Labatec Pharma launches Eroxon® in the UAE

UAE becomes the first market in the Middle East to make Eroxon®available for men, an over the counter, FDA-approved gel for erectile dysfunction.

Dubai, UAE:Labatec Pharma, a leading Swiss-based pharmaceutical company, has announced the UAE launch of Eroxon®, an innovative gel-based topical treatment for erectile dysfunction (ED). The UAE becomes the first market in the Middle Eastwhere the treatment is available following its recent regulatory approval. Distribution and retailing of the product inside the UAE will commence in October with Eroxon® available over the counter at local pharmacies.

Eroxon® is a U.S.FDA-approved over the countererectile dysfunction topical treatment. Eroxon is also approved as a CE device in Europe and the United Kingdom. Studies have demonstrated that it presents an effective, clinically proven treatment for erectile dysfunction with a rapid speed of onset and a favourable benefit versus risk profile, which is ideally suited for an over-the-counter classification. It is therefore of particular appeal to mild to moderate ED patients.